STOCK TITAN
  1. Home
  2. News
  3. ECOR

electroCore to Participate in the Lytham Partners Fall 2023 Virtual Investor Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
electroCore CEO to participate in Lytham Partners Fall 2023 Investor Conference
Positive
  • electroCore CEO, Dan Goldberger, will be participating in the Lytham Partners Fall 2023 Investor Conference on October 17, 2023.
Negative
  • None.

ROCKAWAY, N.J., Oct. 05, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, will be participating in the Lytham Partners Fall 2023 Investor Conference taking place virtually on Tuesday, October 17, 2023.

1x1 Meetings

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register at https://www.lythampartners.com/fall2023invreg/.

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.

For more information, visit www.electrocore.com.

Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com


The conference is taking place on October 17, 2023.

electroCore CEO, Dan Goldberger, will be participating.

To arrange a meeting, please contact Lytham Partners at 1x1@lythampartners.com or register at https://www.lythampartners.com/fall2023invreg/.
Stock ECOR logo
ElectroCore Inc

NASDAQ:ECOR

ECOR Rankings

#4931 Ranked by Market Cap
#411 Ranked by Stock Gains
N/A Ranked by Dividends

ECOR Latest News

Apr 8, 2024
electroCore Announces the Launch of Truvaga Plus® for General Wellness
Apr 2, 2024
electroCore Expands Intellectual Property Portfolio
Mar 13, 2024
electroCore Announces Fourth Quarter and Full Year 2023 Financial Results
Mar 12, 2024
electroCore to Participate in Upcoming Investor Conferences
Mar 5, 2024
electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2023 Financial Results on Wednesday, March 13, 2024

ECOR Stock Data

Electromedical and Electrotherapeutic Apparatus Manufacturing
Manufacturing
Health Technology, Medical Specialties, Manufacturing, Electromedical and Electrotherapeutic Apparatus Manufacturing
United States

About ECOR

electrocore is, a us based electroceutical healthcare company, which is developing a range of non-invasive vagus nerve stimulation (nvns) patient administered therapies for the treatment of multiple conditions in neurology, psychiatry, gastroenterology and other fields. initial focus is on primary headache (migraine and cluster headache), with trials continuing in epilepsy, gastric motility disorders, depression and anxiety. electrocore, which was founded in 2005, has more than 30 employees and full time consultants with offices in the us (head office), germany (german and european head office), uk, italy, australia, and canada.